---
title: "Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis"
id: "journal-of-clinical-oncology-8-past-present-and-future-of-dexamethasone-in-multiple-myeloma-and-al-amyloidosis"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-8-past-present-and-future-of-dexamethasone-in-multiple-myeloma-and-al-amyloidosis"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Journal of Clinical Oncology (JCO)"
source_url: "https://ascopubs.org/doi/abs/10.1200/JCO-25-01713?af=R"
published_at: "2026-01-27T08:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-8-past-present-and-future-of-dexamethasone-in-multiple-myeloma-and-al-amyloidosis
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Journal of Clinical Oncology (JCO)
- **Source URL:** [Original Journal Publication](https://ascopubs.org/doi/abs/10.1200/JCO-25-01713?af=R)
- **Published At:** 2026-01-27T08:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Jan 2026. The item focuses on Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis. Review the original article for the full source wording and details.
## Clinical Analysis & Structured Key Points
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Jan 2026. The item focuses on Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis. Review the original article for the full source wording and details.
## Related Clinical Research

- [Global inequities in seminal studies underlying chemotherapy-induced nausea and vomiting guidelines](https://medichelpline.com/clinical-feed/pubmed-42601561.md) (DOI: 10.1007/s00520-026-11103-0)
- [FDA approves Zenbexus (iberdomide) for multiple myeloma, first of a novel drug class](https://medichelpline.com/clinical-feed/stat-news-1-stat-fda-approves-bristol-multiple-myeloma-treatment-marking-debut-of-novel.md)
- [HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl.md)
- [Selinexor plus bortezomib, lenalidomide, dexamethasone (XVRd) in newly diagnosed high‑risk multipl](https://medichelpline.com/clinical-feed/pubmed-42544613.md) (DOI: 10.1080/07853890.2026.2703403)
- [Integrating talquetamab regimens in early relapsed/refractory multiple myeloma: implications and o](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-more-options-more-questions-in-the-management-of-early-relapsed-and-or.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.